Fig. 1From: Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetateReduction of annualized relapse rate by geographic region. aP < .0001 vs. baseline. *The overall population size does not each the sum of the three individual regions due to four patients in Taiwan that excluded from the regional analysis. ARR annualized relapse rateBack to article page